Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTryptamine Therapeutics Ltd

Tryptamine Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-02-23T06:45:06.402524Z
Market Cap
54.72M

Momentum Score

…

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
1.58M
Revenue Per Share
0.00
Gross Profit TTM
-0.82M
Debt / Equity
-
ROE
-92.07%
Net Debt
-4.42M
ROCE
-230.20%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.13M -10.08M -8.47M -5.28M -2.28M
Net income -7.13M -10.17M -8.46M -5.22M -2.19M
Selling general administrative 6.41M 9.39M 7.90M 4.65M 1.36M
Selling and marketing expenses 0.09M 0.29M 0.33M 0.14M -
Gross profit -1.12M -4.09M 3.19M 2.23M -0.06M
Reconciled depreciation 1.70M 1.73M 1.01M 0.38M -
Ebit -9.59M -10.00M -9.59M -6.13M -2.69M
Ebitda -7.85M -8.30M -7.86M -5.13M -2.31M
Depreciation and amortization 1.74M 1.70M 1.73M 1.01M 0.38M
Operating income -6.80M -10.00M -12.67M -8.00M -2.37M
Other operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Interest expense 0.33M 0.08M - - -
Tax provision 0.00M 0.00M 0.00M 0.00M -
Interest income 0.02M 0.00M 0.01M 0.06M -
Net interest income -0.31M -0.08M 0.01M 0.06M -
Income tax expense - 0.08M -0.01M -0.06M -0.09M
Total revenue 0.62M 0.10M 4.19M 2.62M -
Total operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Cost of revenue 1.74M 4.19M 1.01M 0.38M 0.06M
Total other income expense net -0.31M -0.08M -0.05M 2.73M 0.03M
Net income from continuing ops -7.13M -10.08M -8.47M -5.28M -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 5.88M 13.61M 21.46M 6.54M 5.40M
Intangible assets 0.28M 0.33M 0.33M 0.33M 0.33M
Other current assets 2.72M 4.17M 3.96M 2.11M 0.11M
Total liab 1.75M 4.81M 2.59M 1.53M 0.28M
Total stockholder equity 4.13M 8.81M 18.87M 5.02M 5.12M
Other current liab - - - - 0.14M
Common stock - - - - 7.58M
Capital stock 36.73M 34.31M 34.30M 12.76M -
Retained earnings -33.42M -26.29M -16.21M -7.74M -2.46M
Cash 1.64M 4.85M 12.72M 1.74M 4.42M
Total current liabilities 1.71M 4.46M 1.77M 0.92M 0.28M
Net debt - - - - -4.42M
Short long term debt 1.53M 2.75M - - -
Other stockholder equity - - - - 0.00M
Total current assets 4.59M 9.46M 17.20M 4.06M 4.58M
Long term investments - - - 0.28M -
Net receivables - - - 0.02M 0.05M
Accounts payable 0.04M 0.21M 0.31M 0.14M 0.04M
Accumulated other comprehensive income - - - - 0.00M
Non currrent assets other - 0.58M 0.45M 0.04M -0.82M
Non current assets total 1.30M 4.15M 4.26M 2.48M 0.82M
Capital lease obligations - 1.00M 1.36M 0.91M -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.28M -1.24M -1.80M -0.95M -
Total cashflows from investing activities -0.28M -1.24M -1.80M -0.95M -0.86M
Total cash from financing activities 0.92M 1.88M 20.61M 4.97M 7.41M
Net income -7.13M -10.17M -8.47M -5.28M -2.28M
Change in cash -3.20M -7.88M 10.98M -2.68M 4.37M
Begin period cash flow 4.85M 12.72M 1.74M 4.42M 0.05M
End period cash flow 1.64M 4.85M 12.72M 1.74M 4.42M
Total cash from operating activities -3.85M -8.44M -7.83M -6.72M -2.18M
Issuance of capital stock 1.57M - 22.00M 5.18M 7.41M
Depreciation 1.74M 1.73M 1.01M 0.38M 0.06M
Other cashflows from investing activities 0.01M -0.11M 0.01M -0.04M -0.33M
Sale purchase of stock - - -0.84M - -
Other cashflows from financing activities 0.92M 1.88M 20.61M 4.97M 7.41M
Capital expenditures 0.28M 1.13M 1.63M 0.63M 0.86M
Change in working capital -1.70M 6.60M 2.83M 0.29M 0.04M
Stock based compensation - 0.02M 0.72M - -
Other non cash items 3.24M 8.44M -2.31M -2.11M 0.05M
Free cash flow -4.13M -9.56M -9.45M -7.35M -3.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Tryptamine Therapeutics Ltd

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.

697 Burke Road, Camberwell, VIC, Australia, 3124

61 3 9092 0475

https://www.tryptherapeutics.com

Name Title Year Born
Dr. James P. Gilligan MSIB, Ph.D. President & Chief Scientific Officer 1952
Mr. Peter Molloy ASIP, B.A., C.F.A. Chief Business Officer & Executive Director 1972
Mr. Jason Carroll MD, CEO & Executive Director NA
Dr. William James Garner M.D., M.P.H., MPH Founder & MD 1966
Mr. Hamish George B.Com., C.A. Chief Financial Officer NA
Dr. James P. Gilligan MSIB, Ph.D. President & Chief Scientific Officer 1952
Mr. Peter Molloy ASIP, B.A., C.F.A. Chief Business Officer & Executive Director 1972
Mr. Jason Carroll MD, CEO & Executive Director NA
Dr. William James Garner M.D., M.P.H., MPH Founder & MD 1966
Mr. Hamish George B.Com., C.A. Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…